We are live on ! Find out more
Rafferty Asset Management

Rafferty Asset Management Portfolio holdings

AUM $24.6B
1-Year Est. Return 47.06%
This Fund
S&P 500
This Quarter Est. Return
+10.61%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$6.5B
AUM Growth
+$106M
Cap. Flow
-$484M
Cap. Flow %
-7.44%
Top 10 Hldgs %
52.66%
Holding
925
New
127
Increased
448
Reduced
289
Closed
61

Sector Composition

Rank Sector Weight
1 Financials 12.12%
2 Technology 8.06%
3 Healthcare 5.67%
4 Energy 5.37%
5 Real Estate 3.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MGNX icon
676
MacroGenics
MGNX
$233M
$544K 0.01%
49,956
-43,335
-46% -$429K
WSO icon
677
Watsco Inc
WSO
$13.2B
$539K 0.01%
2,990
+306
+11% +$53.8K
YMAB
678
DELISTED
Y-mAbs Therapeutics
YMAB
$530K 0.01%
+16,962
New +$502K
BOKF icon
679
BOK Financial
BOKF
$8.58B
$527K 0.01%
6,034
+270
+5% +$22K
BDN
680
Brandywine Realty Trust
BDN
$509M
$526K 0.01%
33,373
+2,767
+9% +$41.8K
MTD icon
681
Mettler-Toledo International
MTD
$28.1B
$522K 0.01%
+658
New +$475K
PGRE
682
DELISTED
Paramount Group
PGRE
$517K 0.01%
37,138
+2,177
+6% +$29.2K
DVAX
683
DELISTED
Dynavax Technologies
DVAX
$512K 0.01%
+89,512
New +$479K
CYTK icon
684
Cytokinetics
CYTK
$10.6B
$509K 0.01%
47,996
-24,648
-34% -$253K
RBC icon
685
RBC Bearings
RBC
$17.4B
$509K 0.01%
3,214
+405
+14% +$65.5K
PGNX
686
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$507K 0.01%
99,608
-29,792
-23% -$158K
BCRX icon
687
BioCryst Pharmaceuticals
BCRX
$2.42B
$504K 0.01%
146,084
-125,292
-46% -$315K
LM
688
DELISTED
Legg Mason, Inc.
LM
$502K 0.01%
13,977
+1,130
+9% +$41.9K
DNLI icon
689
Denali Therapeutics
DNLI
$3.79B
$500K 0.01%
28,690
-27,690
-49% -$461K
MRCY icon
690
Mercury Systems
MRCY
$5.41B
$493K 0.01%
7,136
-3,605
-34% -$260K
TWST icon
691
Twist Bioscience
TWST
$5.32B
$488K 0.01%
23,258
-21,488
-48% -$503K
MORN icon
692
Morningstar
MORN
$7.55B
$484K 0.01%
3,200
+258
+9% +$39.6K
TREX icon
693
Trex
TREX
$4.4B
$480K 0.01%
10,684
+1,066
+11% +$46.9K
RYTM icon
694
Rhythm Pharmaceuticals
RYTM
$7.31B
$479K 0.01%
20,847
-7,134
-25% -$158K
CVCO icon
695
Cavco Industries
CVCO
$4.36B
$478K 0.01%
2,447
+242
+11% +$47.4K
EVR icon
696
Evercore
EVR
$11.8B
$472K 0.01%
6,314
+396
+7% +$30.2K
TFX icon
697
Teleflex
TFX
$5.96B
$471K 0.01%
+1,251
New +$431K
AXSM icon
698
Axsome Therapeutics
AXSM
$11.7B
$470K 0.01%
4,545
-8,285
-65% -$335K
VET icon
699
Vermilion Energy
VET
$1.66B
$467K 0.01%
28,565
-27,778
-49% -$418K
CXP
700
DELISTED
COLUMBIA PROPERTY TRUST, INC.
CXP
$466K 0.01%
22,272
+1,847
+9% +$37.9K

Similar funds

Rafferty Asset Management's Q4 2019 Portfolio in Review

As of Q4 2019, Rafferty Asset Management held 925 positions worth $6.5B, up 1.7% from $6.39B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Rafferty Asset Management withdrew a net $484M in Q4 2019, closing 61 positions and reducing 289 holdings. Its most notable exit was State Street Health Care Select Sector SPDR ETF, an estimated $83.7M position sold in full.

By sector, the portfolio is most concentrated in Financials at 12% of assets, up from 11% a quarter earlier, followed by Technology and Healthcare.

Against the trend, Rafferty Asset Management opened a new position in Moderna worth $3.18M.

  • Rafferty Asset Management's largest Q4 2019 buy was Moderna: 162,744 shares worth $3.18M.
  • Rafferty Asset Management added most to iShares Core S&P 500 ETF in Q4 2019, an estimated $56.2M increase.
  • Rafferty Asset Management's biggest Q4 2019 reduction was iShares Russell 2000 ETF, cutting an estimated $94.9M.
  • Rafferty Asset Management fully exited State Street Health Care Select Sector SPDR ETF in Q4 2019, selling an estimated $83.7M.
  • Rafferty Asset Management's ten largest holdings make up 53% of its $6.5B portfolio in Q4 2019.
  • Rafferty Asset Management opened 127 new positions and closed 61 in Q4 2019.
  • Rafferty Asset Management's portfolio value rose 1.7% quarter-over-quarter to $6.5B.

Based on Rafferty Asset Management's 13F filing for Q4 2019, filed 10 Feb 2020.